Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 배상철 | - |
dc.date.accessioned | 2018-07-16T01:19:11Z | - |
dc.date.available | 2018-07-16T01:19:11Z | - |
dc.date.issued | 2016-06 | - |
dc.identifier.citation | RHEUMATOLOGY INTERNATIONAL, v. 36, NO 6, Page. 837-844 | en_US |
dc.identifier.issn | 0172-8172 | - |
dc.identifier.issn | 1437-160X | - |
dc.identifier.uri | https://link.springer.com/article/10.1007%2Fs00296-016-3476-5 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/72573 | - |
dc.description.abstract | We aimed to investigate whether the PTPRC rs10919563 A/G and Fc gamma receptor 2A (FCGR2A) R131H polymorphisms can predict the response to anti-TNF therapy in rheumatoid arthritis (RA) patients. We conducted a meta-analysis of studies on the association between the PTPRC rs10919563 A/G or the FCGR2A R131H polymorphism and responsiveness to anti-TNF therapy in RA patients. Eighteen studies (twelve on PTPRC and six on FCGR2A) from eight articles involving 3058 patients were considered in this meta-analysis. The meta-analysis showed a significant association between the PTPRC rs10919563 A allele and response to TNF-alpha blockers in RA. The OR of the PTPRC A allele was significantly lower in responders (OR = 0.584, 95 % CI = 0.409-0.835, P = 0.003). Meta-analysis revealed no association between the FCGR2A HH + HR genotype and responsiveness to TNF blockers in all study subjects (OR = 0.762, 95 % CI = 0.543-1.068, P = 0.115). However, stratification by TNF inhibitor type showed that the FCGR2A HH + HR genotype was associated with responsiveness to adalimumab (OR = 0.591, 95 % CI = 0.369-0.947, P = 0.029), but not infliximab and etanercept (OR = 0.929, 95 % CI = 0.354-2.440, P = 0.881; OR = 0.804, 95 % CI = 0.293-2.207, P = 0.673). The PTPRC rs10919563 A allele shows a poor response to anti-TNF therapy, and the FCGR2A HH + HR genotype shows a poor response to adalimumab for RA. Genotyping for these polymorphisms may be useful for predicting the response to TNF-alpha blockers with respect to personalized medicine. | en_US |
dc.description.sponsorship | This study was supported in part by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (HI13C2124). | en_US |
dc.language.iso | en | en_US |
dc.publisher | SPRINGER HEIDELBERG | en_US |
dc.subject | Rheumatoid arthritis | en_US |
dc.subject | TNF blockers | en_US |
dc.subject | PTPRC | en_US |
dc.subject | FCGR polymorphism | en_US |
dc.subject | Responsiveness | en_US |
dc.title | Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis | en_US |
dc.type | Article | en_US |
dc.relation.no | 6 | - |
dc.relation.volume | 36 | - |
dc.identifier.doi | 10.1007/s00296-016-3476-5 | - |
dc.relation.page | 837-844 | - |
dc.relation.journal | RHEUMATOLOGY INTERNATIONAL | - |
dc.contributor.googleauthor | Lee, Young Ho | - |
dc.contributor.googleauthor | Bae, Sang-Cheol | - |
dc.relation.code | 2016003713 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | scbae | - |
dc.identifier.orcid | http://orcid.org/0000-0003-4658-1093 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.